Efficacy of Combined Oral L-ornithine-L-aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy

Data collection

1. Baseline characteristics

• demographic data; age, gender, BW, height
• cirrhosis; cause, duration, Child-Pugh score,complications of cirrhosis such as EV, ascites, hepatic encephalopathy, SBP etc.
• comorbidity such as DM, CVA

2. After randomization

• assessment of mental status (West-Haven criteria), Portal-systemic encephalopathy index (PSEI), number connection test, serum ammonia, asterixis at Day 1,3,7 and EEG at day 1,7
• blood chemistry such as CBC, BUN, Creatinine, electrolyte, LFT, coagulogram, BS at Day 1,3,7
• record adverse effect of drug such as nausea, vomiting, bloating.
• record diet, frequency of bowel movement and stool pH
• compliance